← Back to Search

Molecular Breast Imaging for Breast Cancer

N/A

Waitlist Available

Led By Gaiane M. Rauch, MD, PHD

Research Sponsored by M.D. Anderson Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Has biopsy-proven invasive breast cancer (BI-RADS 6) and scheduled for neoadjuvant chemotherapy (NAC)

Newly diagnosed biopsy proven locoregional invasive breast cancer at MD Anderson Cancer Center, or referred to MD Anderson for treatment after initial radiologic (mammographic, sonographic, etc.) exams at an outside institution in whom NAC is planned

Must not have

Is under 18 years of age

Has lesions involving chest wall

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 24 weeks

Awards & highlights

All Individual Drugs Already Approved

No Placebo-Only Group

Approved for 5 Other Conditions

Summary

This trial looks at using technetium Tc-99m sestamibi to see if it can predict how well patients with breast cancer that has spread to nearby tissues will respond to chemotherapy.

Who is the study for?

This trial is for women over 18 with newly diagnosed invasive breast cancer that hasn't spread beyond the local area and who are scheduled for chemotherapy. They must not be pregnant, nursing, or allergic to Tc99m sestamibi.

What is being tested?

The study tests if a special imaging technique using technetium Tc-99m sestamibi can predict how well patients respond to pre-surgery chemotherapy in treating locoregional breast cancer.

What are the potential side effects?

While the document doesn't list specific side effects of Tc99m sestamibi MBI, common ones may include discomfort from the imaging procedure and rare allergic reactions to the tracer.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have invasive breast cancer confirmed by biopsy and am scheduled for chemotherapy before surgery.

Select...

I have been newly diagnosed with invasive breast cancer and am planning to receive neoadjuvant chemotherapy.

Select...

My breast cancer is at stage T1-T4, may have spread to nearby lymph nodes but not to distant parts of the body.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I am younger than 18 years old.

Select...

My cancer has spread to my chest wall.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 24 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~24 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Detection of Treatment Response using Molecular Breast Imaging (MBI) plus Tc99m sestamibi

Awards & Highlights

All Individual Drugs Already Approved

Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Approved for 5 Other Conditions

This treatment demonstrated efficacy for 5 other conditions.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Molecular Breast Imaging (MBI) + Tc99m sestamibiExperimental Treatment2 Interventions

Participants undergo 3 MBI scans with injections of injection of Tc99m sestamibi before each scan. First scan is 7 days before scheduled chemotherapy treatment, after 2 cycles of chemotherapy, and after completion of chemotherapy treatment.

0 / 5Eligibility criteria met